WO2019196606A1 - Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux - Google Patents

Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux Download PDF

Info

Publication number
WO2019196606A1
WO2019196606A1 PCT/CN2019/078703 CN2019078703W WO2019196606A1 WO 2019196606 A1 WO2019196606 A1 WO 2019196606A1 CN 2019078703 W CN2019078703 W CN 2019078703W WO 2019196606 A1 WO2019196606 A1 WO 2019196606A1
Authority
WO
WIPO (PCT)
Prior art keywords
less
mol
tumor
animal
animal model
Prior art date
Application number
PCT/CN2019/078703
Other languages
English (en)
Inventor
Loc VAN
Original Assignee
Primordial Biotech. Co.
Shanghai Lide Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primordial Biotech. Co., Shanghai Lide Biotech Co., Ltd. filed Critical Primordial Biotech. Co.
Priority to JP2021504560A priority Critical patent/JP7478720B2/ja
Priority to US17/046,981 priority patent/US20210047622A1/en
Priority to EP19784485.5A priority patent/EP3775170A4/fr
Priority to SG11202010129WA priority patent/SG11202010129WA/en
Priority to AU2019250859A priority patent/AU2019250859A1/en
Priority to CN201980039991.5A priority patent/CN112334575A/zh
Priority to CA3096561A priority patent/CA3096561A1/fr
Priority to KR1020207032894A priority patent/KR20210005073A/ko
Publication of WO2019196606A1 publication Critical patent/WO2019196606A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0271—Chimeric animals, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Definitions

  • the present invention relates to a composition for propagating a primary tumor cell obtained from a tumor biopsy sample of a patient under both in vitro and in vivo conditions, a method for propagating the obtained primary tumor cell in the composition, a method for obtaining an animal model for screening the efficacy of an anti-tumor drug using the animal model.
  • Conditional reprogramming is a cell culture technique that can be used to rapidly and efficiently establish patient-derived cell cultures from both normal and diseased cells, including tumor cells.
  • the greatest advantage of CR is its rapid and efficient expansion of cell cultures from patient tissue samples. This allows researchers to screen tumors for sensitivity to anticancer drugs or immunotherapies quickly enough to provide the information for clinical use.
  • an anti-tumor drug in an animal model for its efficacy is important as such animal model is important for anti-tumor drug screening.
  • Such an animal model will mimic the in vivo environment of patients, reflect the patient’s response and thus is more effective.
  • a person skilled in the art usually need to obtain sufficiently large number of tumor cells.
  • tumor samples obtained from patients may contain very small or even trace amount of tumor cells depending on how they are obtained.
  • a tumor sample obtained from needle biopsy may contain very small amount of tumor cells and thus very difficult for a person skilled in the art to use them to establish a desired animal model for screening anti-tumor drugs.
  • Tumor cell immortalization through conditional reprogramming is an invaluable tool to generate propagating tumor cells for cell-based diagnostics, drug sensitivity assay and bio-banking in vitro.
  • how to effectively and successfully cultivate primary tumor cells obtained from patients, especially low or even trace amount of cell samples from e.g. a needle biopsy, is still a challenge.
  • the inventor has successfully conditionally reprogrammed primary tumor cells from a number of tumor types towards immortalization and use the conditionally reprogrammed tumor cells to establish an animal model for testing anti-tumor drugs.
  • the primary tumor cells are obtained from surgery tissues, biopsy or needle biopsy samples.
  • the conditionally reprogrammed primary tumor cells obtained in the present invention exhibited typical colonized growth, which is well maintained upon cryo-frozen. In some cases, the cells can be passaged for multiple times and become useful cell lines. Like primary tumor cells, conditional reprogrammed tumor cells are reliable to test drug sensitivity in vitro.
  • conditional reprogrammed tumor cells CRC
  • the present invention also discloses the use of conditional reprogrammed tumor cells in drug efficacy tests.
  • One aspect of the present invention provides a method for obtaining an animal model for screening anti-tumor drugs, comprising
  • composition comprising:
  • the composition in step (1) of the method of the present invention comprises:
  • the tumor biopsy sample is a needle biopsy sample.
  • the concentration of the primary tumor cells in the sample obtained from a needle biopsy is less than about 2mol/L, less than about 1.9mol/L, less than about 1.8mol/L, less than about 1.7mol/L, less than about 1.6mol/L, less than about 1.5mol/L, less than about 1.4 mol/L, less than about 1.3 mol/L, less than about 1.2 mol/L, less than about 1.1 mol/L, less than about 1.0 mol/L, less than about 0.9 mol/L, less than about 0.8 mol/L, less than about 0, 7 mol/L, less than about 0.6 mol/L, less than about 0.5 mol/L, less than about 0.4 mol/L, less than about 0.3 mol/L, less than about 0.2 mol/L, less than about 0.1 mol/L or less, such as less than about 2 mol/L, less than about 1.7 mol/L, less than about 1.4 mol/L
  • the animal in the present invention is a mouse or a rat, in particular an immunodeficient mouse, such as a nude mouse.
  • the primary tumor cell obtained in step (1) was implanted in to the animal in a hollow fiber.
  • the hollow fiber is made of modified polyvinylidene fluoride, more particularly the hollow fiber is made of modified polyvinylidene fluoride and has a cut-off value of 500,000 Dalton.
  • Another aspect of the present invention provides an animal model for screening anti-tumor drugs obtained by the method of the present invention.
  • the animal in the present invention is a mouse or a rat, in particular an immunodeficient mouse, such as a nude mouse.
  • Another aspect of the present invention provides a method for screening anti-tumor drugs using the animal model of the present invention, comprising administering a candidate drug to the animal model of the present invention.
  • the above method further comprises measuring tumor cell growth in the animal model of the present invention.
  • Figure 1 shows the morphology of conditionally reprogrammed cells in growing colonies from various tumor samples.
  • A P0, P4 and P6 passages of conditionally reprogrammed primary cells originated from surgical sample of a lung cancer patient;
  • B P3 conditionally reprogrammed cells originated from biopsy sample of a lung cancer patient;
  • C P4 conditionally reprogrammed cells originated from a needle biopsy sample of an adenoid cystic carcinoma patient;
  • D P12 cell originated from a needle biopsy sample of a peritoneal mesothelioma patient;
  • E P7 cell originated from a surgical sample of a glioblastoma patient;
  • F P6 cell originated from a biopsy sample of a colonrectal cancer patient;
  • G P3 cell originated from a surgical sample of a gallbladder carcinoma patient.
  • Figure 2 A The results of anti-tumor efficacy of test drug in MDX079 Mini-PDX models; B, The results of anti-tumor efficacy of test drug in MDX083 Mini-PDX models; C, The results of anti-tumor efficacy of test drug in MDX095 Mini-PDX models; D, The results of anti-tumor efficacy of test drug in MDX107 Mini-PDX models; E, The results of anti-tumor efficacy of test drug in MDX123 Mini-PDX models.
  • Figure 3 A The results of anti-tumor efficacy of test drug in MDX133 Mini-PDX models
  • B The results of anti-tumor efficacy of test drug in MDX154 Mini-PDX models
  • C The results of anti-tumor efficacy of test drug in MDX164 Mini-PDX models
  • D The results of anti-tumor efficacy of test drug in MDX165 Mini-PDX models
  • E The results of anti-tumor efficacy of test drug in MDX168 Mini-PDX models.
  • F The results of anti-tumor efficacy of test drug in MDX169 Mini-PDX models
  • G The results of anti-tumor efficacy of test drug in MDX174 Mini-PDX models
  • H The results of anti-tumor efficacy of test drug in MDX186 Mini-PDX models
  • I The results of anti-tumor efficacy of test drug in MDX189 Mini-PDX models
  • J The results of anti-tumor efficacy of test drug in MDX203 Mini-PDX models.
  • One aspect of the present invention provides a method for obtaining an animal model for screening anti-tumor drugs, comprising (1) cultivating a primary tumor cell obtained from a tumor biopsy sample of a patient in a composition comprising:
  • the tumor biopsy sample is a needle biopsy sample.
  • the concentration of tumor cells in the sample obtained from the needle biopsy is less than about 2mol/L.
  • the concentration of hydrocortisone in the composition of step (1) can be 0.01-1.0 mg/L, in particular about 0.05-1.0 mg/L, about 0.1-1.0 mg/L, about 0.1-0.9 mg/L, about 0.2-0.8 mg/L, about 0.2-0.7 mg/L, about 0.25-0.65mg/L, about 0.25-0.6mg/L, about 0.3-0.5mg/L, about 0.35-0.55mg/L, about 0.35-0.4mg/L, about 0.4-0.45mg/L, about 0.35-0.45mg/L, about 0.45-0.55mg/L, about 0.05 mg/L, about 0.1 mg/L, about 0.2 mg/L, about 0.3 mg/L, about 0.31 mg/L, about 0.32 mg/L, about 0.33 mg/L, about 0.34 mg/L, about 0.35 mg/L, about 0.36 mg/L, about 0.37 mg/L, about 0.38 mg/L, about 0.39 mg/L, about 0.4 mg/L, about
  • the concentration of insulin in the composition of step (1) can be 1.0-10 mg/L, in particular about 1-10 mg/L, about 2-9 mg/L, about 3-8 mg/L, about 3-7 mg/L, about 4.5-6.5 mg/L, about 4-6 mg/L, about 1 mg/L, about 2 mg/L, about 3 mg/L, about 4 mg/L, about 5 mg/L, about 6 mg/L, about 7 mg/L, about 8 mg/L, about 9 mg/L, about 10 mg/L.
  • the concentration of cholera toxin in the composition of step (1) can be 1-20 ⁇ g/L, in particular about 2-20 ⁇ g/L, about 3-18 ⁇ g/L, about 4-15 ⁇ g/L, about 5-10 ⁇ g/L, about 6-10 ⁇ g/L, about 7-9 ⁇ g/L, about 7.5-8.5 ⁇ g/L, about 1 ⁇ g/L, about 2 ⁇ g/L, about 3 ⁇ g/L, about 4 ⁇ g/L, about 5 ⁇ g/L, about 6 ⁇ g/L, about 7 ⁇ g/L, about 8 ⁇ g/L, about 8.1 ⁇ g/L, about 8.2 ⁇ g/L, about 8.3 ⁇ g/L, about 8.4 ⁇ g/L, about 8.5 ⁇ g/L, about 8.6 ⁇ g/L, about 8.7 ⁇ g/L, about 8.8 ⁇ g/L, about 8.9 ⁇ g/L, about 9 ⁇ g/L, about 10 ⁇ g/L, about
  • the concentration of adenine in the composition of step (1) can be 2-50 mg/L, in particular about 5-40 mg/L, about 10-30 mg/L, about 15-30 mg/L, about 20-30 mg/L, about 22-27 mg/L, about 23-26 mg/L, about 24-25 mg/L, about 2 mg/L, about 6 mg/L, about 8 mg/L, about 10 mg/L, about 12 mg/L, about 14 mg/L, about 16 mg/L, about 18 mg/L, about 20 mg/L, about 21 mg/L, about 22 mg/L, about 23 mg/L, about 24 mg/L, about 24.1 mg/L, about 24.2 mg/L, about 24.3 mg/L, about 24.4 mg/L, about 24.5 mg/L, about 24.6 mg/L, about 24.7 mg/L, about 24.8 mg/L, about 24.9 mg/L, about 25 mg/L, about 26 mg/L, about 27 mg/L, about 28 mg/L, about 29 mg/L, about 30 mg/L, about 35 mg
  • the concentration of EGF in the composition of step (1) can be 1-30 ⁇ g/L, in particular about 2-20 ⁇ g/L, about 4-18 ⁇ g/L, about 6-16 ⁇ g/L, about 8-12 ⁇ g/L, about 9-11 ⁇ g/L, about 9.5-10.5 ⁇ g/L, about 2 ⁇ g/L, about 4 ⁇ g/L, about 6 ⁇ g/L, about 7 ⁇ g/L, about 8 ⁇ g/L, about 9 ⁇ g/L about 10 ⁇ g/L, about 11 ⁇ g/L, about 12 ⁇ g/L, about 14 ⁇ g/L, about 16 ⁇ g/L, about 18 ⁇ g/L, about 20 ⁇ g/L, about 25 ⁇ g/L, about 30 ⁇ g/L.
  • the concentration of Y-27632 in the composition of step (1) can be 1-30 ⁇ mol/L, in particular about 2-20 ⁇ mol/L, about 4-18 ⁇ mol/L, about 6-16 ⁇ mol/L, about 8-12 ⁇ mol/L, about 9-11 ⁇ mol/L, about 9.5-10.5 ⁇ mol/L, about 2 ⁇ mol/L, about 4 ⁇ mol/L, about 6 ⁇ mol/L, about 7 ⁇ mol/L, about 8 ⁇ mol/L, about 9 ⁇ mol/L, about 10 ⁇ mol/L, about 11 ⁇ mol/L, about 12 ⁇ mol/L, about 14 ⁇ mol/L, about 16 ⁇ mol/L, about 18 ⁇ mol/L, about 20 ⁇ mol/L, about 25 ⁇ mol/L, about 30 ⁇ mol/L.
  • the concentration of FBS the composition of step (1) can be 2-20%, in particular about 4-15%, about 5-18%, about 6-16%, about 7-14%, about 8-12%, about 9-11%, about 9.5-10.5%, about 2%, about 4 %, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 14%, about 16 %, about 18%, about 20%.
  • the present invention provides a method for obtaining an animal model for screening anti-tumor drugs, comprising (1) cultivating a primary tumor cell obtained from a tumor biopsy sample of a patient in a composition comprising:
  • the tumor biopsy sample is a needle biopsy sample.
  • the concentration of the primary tumor cells in the sample obtained from a needle biopsy is less than about 2mol/L, less than about 1.9mol/L, less than about 1.8mol/L, less than about 1.7mol/L, less than about 1.6mol/L, less than about 1.5mol/L, less than about 1.4 mol/L, less than about 1.3 mol/L, less than about 1.2 mol/L, less than about 1.1 mol/L, less than about 1.0 mol/L, less than about 0.9 mol/L, less than about 0.8 mol/L, less than about 0, 7 mol/L, less than about 0.6 mol/L, less than about 0.5 mol/L, less than about 0.4 mol/L, less than about 0.3 mol/L, less than about 0.2 mol/L, less than about 0.1 mol/L or less, such as less than about 2 mol/L
  • the animal in the method of the present invention is a mouse or a rat, in particular an immunodeficient mouse, such as a nude mouse.
  • the primary tumor cell obtained in step (1) was implanted in to the animal in a hollow fiber.
  • the hollow fiber is made of modified polyvinylidene fluoride, more particularly the hollow fiber is made of modified polyvinylidene fluoride and has a cut-off value of 500,000 Dalton.
  • Another aspect of the present invention provides an animal model for screening anti-tumor drugs obtained by the method of the present invention.
  • the animal in the present invention is a mouse or a rat, in particular an immunodeficient mouse, such as a nude mouse.
  • Another aspect of the present invention provides a method for screening anti-tumor drugs using the animal model of the present invention, comprising administering a candidate drug to the animal model of the present invention.
  • the above method further comprises measuring tumor cell growth in the animal model of the present invention.
  • the tumor cells can be obtained from a variety of tumor types, including but not limited to tumors in the digestive tract (such as the stomach, intestines, duodenum, colon, pancreas, etc. ) , the breast, lung, liver, and endocrine glands (such as the adrenal gland, parathyroid gland, pituitary, testis, ovaries, and thymus, thyroid gland) , urinary and reproductive systems (such as kidney, bladder, ovary, testis, prostate, etc. ) , skeletal muscle system (such as bone, smooth muscle, striated muscle, etc. ) , skin, and so on.
  • the tumor cells can be derived from gastric cancer, biopsy specimen of twelve colorectal cancer and lung cancer.
  • conditionally reprogrammed primary tumor cells can be implanted into the animal via a syringe or other methods or devices known in the art.
  • the conditionally reprogrammed primary tumor cells are implanted into an animal by a method for producing a PDX model for tumor growth in vivo. See e.g. “Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions” , Oncotarget, Vol. 5, No. 20, Berglind O. Einarsdottir et.
  • conditionally reprogrammed primary tumor cells were transferred into a hollow-fiber tube, which is then implanted into an animal.
  • the hollow fiber can be made of modified polyvinylidene fluoride and has a cut-off value of 500,000 Dalton.
  • a mini-PDX device in the refers to a hollow fiber can be made of modified polyvinylidene fluoride and has a cut-off value of 500,000 Dalton, which may contain the primary tumor cells obtained from a patient and be implanted into a candidate animal, e.g. implanted into a candidate animal subcutaneously.
  • a mini-PDX model refers to an animal that has been implanted with the mini-PDX device of the present invention.
  • the mini-PDX animal model can be used in the methods/tests described in the present invention.
  • Another aspect of the present invention provides a method for screening anti-tumor drugs using the animal model of the present invention, comprising administering a candidate drug to the animal model of the present invention.
  • the method further comprises measuring the growth of the tumor cells which is carried by the animal model of the present invention before and after said administration.
  • the size of the tumor is measured before and 5-14 days, in particular 5-7 days after administering the drug to the animal model of the present invention.
  • tumor cell apoptosis is measured before and 5-14 days, in particular 5-7 days after administering the drug to the animal model of the present invention.
  • tumor cell differentiation is measured before and 5-14 days, in particular 5-7 days after administering the drug to the animal model of the present invention.
  • a person skilled in the art will choose a suitable method to measure the growth of the tumor cells which is carried by the animal model of the present invention before and after said administration.
  • the drug can be administered via any suitable route, either oral or parental.
  • the candidate drug is administered to the animal model of the present invention by oral administration or intramuscular injection (such as through intramuscular, subcutaneous or intravenous infusion) , local administration, inhalation, and transdermal delivery such as skin patches, implants, suppositories, etc.
  • oral administration or intramuscular injection such as through intramuscular, subcutaneous or intravenous infusion
  • local administration inhalation
  • transdermal delivery such as skin patches, implants, suppositories, etc.
  • a skilled person in the art will choose a suitable route of administration according to their needs.
  • the candidate drugs to be screened in the present invention may be a known antitumor drug or its combination, a new antitumor or a combination, or a new combination of known antitumor drugs.
  • the drug to be screened can be used in solid, semi-solid or liquid form.
  • the candidate animals can be administered with the drugs by oral administration or intramuscular injection (such as through intramuscular, subcutaneous or intravenous infusion) , local administration, inhalation, and transdermal delivery such as skin patches, implants, suppositories, etc. Technicians in this field will choose a suitable route of administration according to their needs.
  • F12 medium (commercially available) , 125 mL DMEM with high glucose (commercially available) , 25 mL 10%FBS (commercially available) , 5 mL hydrocortisone, 5 mL insulin, 5 mL cholera toxin, 5 mL adenine, 5 mL Pen/Strep (commercially available) , 5 mL EGF, 1mL Y-27632.
  • Non-Essential Amino Acids Solution commercially available
  • GlutaMAX Supplement commercially available
  • Hydrocortisone dissolve 25 mg commercially available Hydrocortisone in 5 mL cold 100%ethanol to make a 5 mg/mL solution. Add 0.8 mL of said 5 mg/mL solution to 100 mL HBES containing 5%fetal bovine serum (FBS) . Filter sterilize and store at –20°C in 10 mL aliquots. The final concentration of hydrocortisone is 0.4mg/L.
  • ⁇ Cholera toxin add 1.2 mL of sterile water to a vial containing1-mg cholera toxin (commercially available) , obtaining a 10 ⁇ M solution. Dilute 50 ⁇ L of said 10 ⁇ M solution into 50 mL HBES containing 0.1%bovine serum albumin. Filter sterilize and store at 4°C in 10 mL aliquots. The final concentration of cholera toxin is 8.3 ⁇ g/L.
  • Insulin dissolve 12.5 mg commercially available insulin in 25 mL of 0.005 M HCL. Filter sterilize with a syringe filter pre-wet with FBS. The final concentration of insulin is 5 mg/L.
  • Adenine dissolve 121 mg commercially available adenine in 50 mL of 0.05 M HCl by stirring for 1 h. Filter sterilize and store at –20°C in 10 mL aliquots. The final concentration of adenine is 24.2 mg/L.
  • EGF Epidermal growth factor
  • the medium was then properly kept in a cool place for use.
  • MEF mouse embryonic fibroblast
  • MDX079 originated from a female lung cancer patient
  • MDX083 model originated from a 27-year old male adenoid cystic carcinoma patient
  • MDX095 model originated from a 54-year old male peritoneal malignant tnesoshelioma patient
  • MDX107 model originated from a 54-year old male glioblastoma patient
  • MDX123 model originated from a 53-year old male colonrectal cancer patient.
  • Balb/c nude, female were purchased from Shanghai Laboratory Animal Center (Lingchang, Shanghai, China, SCXK (SH) 2013-0018) .
  • mice were kept in SPF room at constant temperature and humidity with 3 animals in each cage.
  • Cages Made of polycarbonate. The size is 325 mm x 210 mm x 180 mm. The bedding material is corn cob, which is changed twice per week.
  • Cage identification the identification labels for each cage contain the following information: number of animals, sex, strain, date received, treatment, study number, group number, and the starting date of the treatment.
  • Animal identification Animals were marked by ear coding.
  • Mini-PDX device a hollow fiber made of modified polyvinylidene fluoride which has a cut-off value of 500,000 Dalton, internal diameter 1-2 mm. Cut into desired length.
  • the cells suspension was filled into Mini-PDX device and the devices were inoculated subcutaneously into both flanks of Nu/Nu-nude mice, to establish the Mini-PDX model.
  • the inoculation day was defined as day 0.
  • Mice were randomized in groups according to the bodyweights and the treatments were initiated at day 0.
  • the test article administration and the mini-PDX device numbers in each study group are shown in the following experimental design tables.
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • Tumor relative proliferation rate (%) (V Td7 -V d0 ) / (V Cd7 -V d0 ) x100%;
  • Tumor relative proliferation rate (%) V Td7 /V Cd7 x100% (V Td7 : the cell viability on day 7 of treatment group; V Cd7 : the cell viability on day 7 of control group; V d0 : the cell viability on day 0) .
  • MDX133 originated from a 45-year old male gastric cancer patient
  • MDX154 model originated from a female gallbladder carcinoma patient
  • MDX164 model originated from a 43-year old male glioblastoma patient
  • MDX165 model originated from a 64-year old male glioblastoma patient
  • MDX168 model originated from a 66-year old female gallbladder carcinoma patient
  • MDX169 model originated from a 52-year old male lung cancer patient
  • MDX174 model originated from a 59-year old male lung cancer patient
  • MDX186 model originated from a 54-year old female pancreatic cancer patient
  • MDX189 model originated from a 44-year old male esophagus cancer patient
  • MDX203 model originated from a 61-year old male gallbladder carcinoma patient.
  • Balb/c nude female, were purchased from Shanghai Laboratory Animal Center (Lingchang, Shanghai, China, SCXK (SH) 2013-0018) .
  • mice were kept in SPF room at constant temperature and humidity with 3 animals in each cage.
  • Cages Made of polycarbonate. The size is 325 mm x 210 mm x 180 mm. The bedding material is corn cob, which is changed twice per week.
  • Cage identification the identification labels for each cage contain the following information: number of animals, sex, strain, date received, treatment, study number, group number, and the starting date of the treatment.
  • Animal identification Animals were marked by ear coding.
  • Mini-PDX device a hollow fiber made of modified polyvinylidene fluoride which has a cut-off value of 500,000 Dalton, internal diameter 1-2 mm. Cut into desired length.
  • the cells suspension was filled into Mini-PDX device and the devices were inoculated subcutaneously into both flanks of Nu/Nu-nude mice, to establish the Mini-PDX model.
  • the inoculation day was defined as day 0.
  • Mice were randomized in groups according to the bodyweights and the treatments were initiated at day 0.
  • the test article administration and the mini-PDX device numbers in each study group are shown in the following experimental design tables.
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • N mini-PDX device number
  • Tumor relative proliferation rate (%) (V Td7 -V d0 ) / (V Cd7 -V d0 ) x100%;
  • Tumor relative proliferation rate (%) V Td7 /V Cd7 x100% (V Td7 : the cell viability on day 7 of treatment group; V Cd7 : the cell viability on day 7 of control group; V d0 : the cell viability on day 0) .
  • T/C% 20%)
  • Tumor cells numbers are counted using methods known in the art and then converted to tumor cell concentration in the suspension. M: mol/L.

Abstract

L'invention concerne un procédé d'obtention d'un modèle animal à partir de cellules tumorales reprogrammées conditionnellement pour le criblage de médicaments antitumoraux et un procédé de criblage de médicaments antitumoraux l'utilisant.
PCT/CN2019/078703 2018-04-13 2019-03-19 Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux WO2019196606A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2021504560A JP7478720B2 (ja) 2018-04-13 2019-03-19 条件付き再プログラム化細胞から動物モデルを得るための方法および抗腫瘍薬のスクリーニングのための動物モデルの使用
US17/046,981 US20210047622A1 (en) 2018-04-13 2019-03-19 Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screeing anti-tumor drugs
EP19784485.5A EP3775170A4 (fr) 2018-04-13 2019-03-19 Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux
SG11202010129WA SG11202010129WA (en) 2018-04-13 2019-03-19 Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screening anti-tumor drugs
AU2019250859A AU2019250859A1 (en) 2018-04-13 2019-03-19 Method for obtaining an animal model from conditionally reprogrammed cells and use of the animal model for screening anti-tumor drugs
CN201980039991.5A CN112334575A (zh) 2018-04-13 2019-03-19 从条件性重编程细胞获得动物模型的方法以及该动物模型用于筛选抗肿瘤药物的用途
CA3096561A CA3096561A1 (fr) 2018-04-13 2019-03-19 Procede d'obtention d'un modele animal a partir de cellules reprogrammees conditionnellement et utilisation du modele animal pour le criblage de medicaments antitumoraux
KR1020207032894A KR20210005073A (ko) 2018-04-13 2019-03-19 조건부 리프로그래밍된 세포에서 동물 모델을 얻는 방법 및 항-종양 약물 스크리닝을 위한 동물 모델의 용도

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018083110 2018-04-13
CNPCT/CN2018/083110 2018-04-13

Publications (1)

Publication Number Publication Date
WO2019196606A1 true WO2019196606A1 (fr) 2019-10-17

Family

ID=68163925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/078703 WO2019196606A1 (fr) 2018-04-13 2019-03-19 Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux

Country Status (9)

Country Link
US (1) US20210047622A1 (fr)
EP (1) EP3775170A4 (fr)
JP (1) JP7478720B2 (fr)
KR (1) KR20210005073A (fr)
CN (1) CN112334575A (fr)
AU (1) AU2019250859A1 (fr)
CA (1) CA3096561A1 (fr)
SG (1) SG11202010129WA (fr)
WO (1) WO2019196606A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113403278A (zh) * 2020-03-16 2021-09-17 合肥中科普瑞昇生物医药科技有限公司 胃癌原代细胞的培养基及培养方法
JP2023513267A (ja) * 2020-02-11 2023-03-30 合肥中科普瑞昇生物医▲薬▼科技有限公司 食道扁平上皮癌の初代細胞用の培養培地、及びその培養方法
EP4331621A1 (fr) * 2022-09-01 2024-03-06 Shanghai Lide Biotech Co., Ltd. Modeles et procedes de criblage rapide de l'efficacite de medicaments immunoregulateurs
JP7464977B2 (ja) 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107976534A (zh) * 2016-10-21 2018-05-01 上海立迪生物技术股份有限公司 一种抗肿瘤药物快速药效筛选方法及其专用装置
CN115029316B (zh) * 2022-06-20 2024-04-30 华中科技大学同济医学院附属协和医院 一种具有放疗敏感和放疗耐受特性的原代宫颈癌细胞系及其构建方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101187A1 (fr) * 2002-05-30 2003-12-11 Raven Biotechnologies, Inc. Modele animal permettant de predire la toxicologie et le dosage
WO2008133359A1 (fr) * 2007-04-27 2008-11-06 Imagene Co., Ltd. Méthode de criblage d'un modulateur immunitaire
WO2014092457A1 (fr) * 2012-12-11 2014-06-19 사회복지법인 삼성생명공익재단 Système de dépistage d'agent anticancéreux personnalisé
CN107541494A (zh) * 2016-06-27 2018-01-05 上海市东方医院 一种人胆管癌细胞系及其应用
CN107541496A (zh) * 2016-06-27 2018-01-05 安徽省立医院 一种人食管癌细胞系及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3252361B2 (ja) * 1991-10-02 2002-02-04 ミルトン・エイチ・リプスキー インビボにおける癌の治療のアッセイ
JP6076258B2 (ja) * 2010-11-12 2017-02-08 ジョージタウン ユニヴァーシティ 上皮細胞の不死化および使用法
JP6602745B2 (ja) * 2013-03-15 2019-11-06 ザ ジャクソン ラボラトリー 非胚性幹細胞の単離とその使用
CN103898056B (zh) * 2014-03-11 2016-09-07 山东大学附属千佛山医院 细胞培养基及其在培养人原代肿瘤细胞中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101187A1 (fr) * 2002-05-30 2003-12-11 Raven Biotechnologies, Inc. Modele animal permettant de predire la toxicologie et le dosage
WO2008133359A1 (fr) * 2007-04-27 2008-11-06 Imagene Co., Ltd. Méthode de criblage d'un modulateur immunitaire
WO2014092457A1 (fr) * 2012-12-11 2014-06-19 사회복지법인 삼성생명공익재단 Système de dépistage d'agent anticancéreux personnalisé
CN107541494A (zh) * 2016-06-27 2018-01-05 上海市东方医院 一种人胆管癌细胞系及其应用
CN107541496A (zh) * 2016-06-27 2018-01-05 安徽省立医院 一种人食管癌细胞系及其应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023513267A (ja) * 2020-02-11 2023-03-30 合肥中科普瑞昇生物医▲薬▼科技有限公司 食道扁平上皮癌の初代細胞用の培養培地、及びその培養方法
JP7454290B2 (ja) 2020-02-11 2024-03-22 合肥中科普瑞昇生物医▲薬▼科技有限公司 食道扁平上皮癌の初代細胞用の培養培地、及びその培養方法
CN113403278A (zh) * 2020-03-16 2021-09-17 合肥中科普瑞昇生物医药科技有限公司 胃癌原代细胞的培养基及培养方法
CN113403278B (zh) * 2020-03-16 2023-02-17 合肥中科普瑞昇生物医药科技有限公司 胃癌原代细胞的培养基及培养方法
JP7464977B2 (ja) 2020-06-10 2024-04-10 国立大学法人東京農工大学 イヌ中皮腫細胞株
EP4331621A1 (fr) * 2022-09-01 2024-03-06 Shanghai Lide Biotech Co., Ltd. Modeles et procedes de criblage rapide de l'efficacite de medicaments immunoregulateurs

Also Published As

Publication number Publication date
CA3096561A1 (fr) 2019-10-17
JP7478720B2 (ja) 2024-05-07
EP3775170A4 (fr) 2022-01-26
JP2021520848A (ja) 2021-08-26
US20210047622A1 (en) 2021-02-18
CN112334575A (zh) 2021-02-05
EP3775170A1 (fr) 2021-02-17
AU2019250859A1 (en) 2020-11-12
KR20210005073A (ko) 2021-01-13
SG11202010129WA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
WO2019196606A1 (fr) Procédé d'obtention d'un modèle animal à partir de cellules reprogrammées conditionnellement et utilisation du modèle animal pour le criblage de médicaments antitumoraux
Li et al. Effectively suppressed angiogenesis-mediated retinoblastoma growth using celastrol nanomicelles
CN109182271A (zh) 基于类器官方法构建正常免疫小鼠人胃癌移植瘤模型的方法和应用
CN109392843A (zh) 基于类器官方法构建卵巢癌移植瘤模型及应用
CN114717190A (zh) 一种人乳腺恶性叶状肿瘤细胞系bpt0713及其应用
CN101003792A (zh) 稳定表达萤火虫荧光素酶的9lluc细胞株的构建与应用
Sobolik et al. Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging
JPWO2019196606A5 (fr)
CN104755610B (zh) 脂肪组织细胞
KR102475776B1 (ko) 암 오가노이드 및 내피 집락 세포를 이용한 대장암 이종이식 동물 모델 및 그 제조방법
CN109929797A (zh) 鸡胚移植瘤模型建立方法及其在药物敏感性检测中的应用
CN109260228A (zh) 一种治疗肿瘤的复合物
Askenasy et al. The topologic and chronologic patterns of hematopoietic cell seeding in host femoral bone marrow after transplantation
Crisanti et al. Novel methods for delivery of cell-based therapies
CN107753143A (zh) 构建胃淋巴瘤动物模型的方法及系统
CN107243006B (zh) Amd3100在制备治疗和/或预防恶液质的药物中的应用
Min et al. Dhh signaling pathway regulates reconstruction of seminiferous tubule-like structure
Keiner et al. Towards a glioma model for surgical technique evaluation in the rat
CN113908145B (zh) 2-[4-[(4-硝基苯基)甲氧基]苯基]乙基氨基亚氨基硫酸酯的应用
CN112544568B (zh) 一种脑胶质母细胞瘤体内替莫唑胺耐药模型的构建方法及耐药细胞的获取方法
CN114796114B (zh) 一种抗肿瘤药物胶束及其制备方法和应用
Ma et al. A PILOT CLINICAL TRIAL OUTCOME OF BIOSAFETY SYSTEM EVALUATION FOR PERV-C FREE PORCINE ISLET XENOTRANSPLANTATION BASED ON PRINCIPLE OF WHO “CHANGSHA COMMUNIQUE”
Chen et al. Optical tissue window: a novel model for optimizing engraftment of intestinal stem cell organoids
CN103110577B (zh) 一种smancs油性制剂、制备方法和用途
Kubelt et al. Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19784485

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3096561

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021504560

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019250859

Country of ref document: AU

Date of ref document: 20190319

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2019784485

Country of ref document: EP